Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT01237119
Previous Study | Return to List | Next Study

Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis (LEAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01237119
Recruitment Status : Completed
First Posted : November 9, 2010
Last Update Posted : March 23, 2016
Wellcome Trust
Novo Nordisk A/S
Information provided by (Responsible Party):
University of Birmingham

Brief Summary:
The purpose of this study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight patients with nonalcoholic steatohepatitis, enough to warrant further investigation.

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis Drug: Liraglutide Other: Liraglutide-placebo Phase 2

Detailed Description:

Non-alcoholic fatty liver disease (NAFLD) is responsible for an increasing prevalence of liver disease and is becoming the commonest cause of liver disease in the western world. NAFLD is recognised to be the hepatic manifestation of the metabolic syndrome, which is a cluster of metabolic abnormalities characterised by abdominal obesity, insulin resistance, impaired glucose metabolism, hypertension and dyslipidaemia. In its mildest form there is an accumulation of fat in the liver (steatosis) without any liver damage, however in many cases it progresses to non-alcoholic steatohepatitis (NASH), and cirrhosis.

Current treatment options for NASH are limited in efficacy, necessitating the development of more effective options. New agents such as Glucagon-like Peptide-1 (GLP-1) agonists that improve diabetic control and facilitate weight loss have been suggested as therapies in NASH.

No published studies to date have assessed the impact of the GLP-1 agonist, Liraglutide, on liver histology and metabolism in obese patients with NASH. This study hypothesises that treatment with liraglutide will result in a significant improvement in histological disease activity in overweight patients with NASH, in the presence or absence of Type 2 Diabetes (T2DM)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes
Study Start Date : August 2010
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014

Arm Intervention/treatment
Experimental: Liraglutide
A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
Drug: Liraglutide
1.8 mg once daily, subcutaneous injection
Other Name: Victoza

Placebo Comparator: Placebo
Liraglutide-Placebo manufactured by Novo Nordisk.
Other: Liraglutide-placebo
1.8 mg once-daily, subcutaneous injection

Primary Outcome Measures :
  1. Liver Histological improvement [ Time Frame: 48 weeks ]

Secondary Outcome Measures :
  1. NAFLD Activity Score [ Time Frame: 48 weeks ]

    Also including:

    Fibrosis panel, Liver Function Tests (LFTs), cytokeratin-18 (CK-18) Glycaemic control, Fibroscan, Quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • NASH on liver biopsy (within 6 months of screening visit).
  • NAFLD Activity Score (NAS) ≥ 3, comprising of a minimum of 1 point from each of the individual steatosis, lobular inflammation and hepatocyte ballooning scores
  • Body Mass Index (BMI) ≥ 25 at randomisation
  • Type 2 Diabetes Mellitus/impaired glucose tolerance or normal glucose tolerance

Exclusion Criteria (brief):

  • Insulin dependent diabetes
  • Glycosylated Haemoglobin (HbA1c) > 9.0%
  • treatment with dipeptidyl peptidase 4 (DPP-IV) inhibitors, Glucagon-like Peptides (GLP) 1 analogues, thiazolidinediones (TZDs)
  • Past Medical History of Acute (or chronic) pancreatitis/pancreatic carcinoma, weight loss surgery, liver transplantation, Medullary thyroid cancer, hepatocellular carcinoma (HCC), Multiple Endocrine Neoplasia (MEN) syndrome, malignancy (within last 3 years, exception of treated skin malignancy)
  • Other liver aetiologies (i.e. drug-induced, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, haemochromatosis, alpha 1 anti-trypsin deficiency, Wilsons disease)
  • concomitant or recent use of orlistat, prednisolone,
  • Refusal or lacks capacity to give informed consent to participate in the trial
  • Participation in any clinical trial of an investigational therapy or agent within 3 months of randomisation
  • Patient (or carer) deemed not competent at using the correct site and technique for subcutaneous injection of the trial treatment (containing dummy drug on practice) at visit 2
  • NAS<3
  • Child's B or C cirrhosis
  • Abnormal clinical examination of thyroid (i.e. unexplained goitre or palpable nodules)
  • Liver enzymes > 10 x upper limit of normal
  • Average alcohol consumption per week > 21 units (210g) male, >14 units (140g) female within the last 5 years.
  • >5% weight loss since the diagnostic liver biopsy was obtained.
  • Recent or concomitant use of steroids (oral), methotrexate, amiodarone, Orlistat
  • Addition or significant change (as judged by the chief investigator) in dose of the following drugs; Angiotensin converting enzymes (ACE)-inhibitors, Angiotensin receptor blockers (ARBs) and/or Multi-vitamins (containing Vitamin E)
  • Known positivity for antibody to Human Immunodeficiency virus (HIV)
  • Serum creatinine > 150 μmol/L or currently being treated with renal replacement therapy
  • Past medical history of multiple drug allergies (defined as anaphylactoid drug reactions in >2 drug groups)
  • Presence of any acute/chronic infections or illness that at the discretion of the chief investigator might compromise the patient's health and safety in the trial
  • Pregnancy or breastfeeding
  • Women, of child-bearing age, who are not willing to practise effective contraception (i.e. barrier, oral contraceptive pill, implanon or history hysterectomy) for the 48 week duration of the trial and for one-month after the last administration of the drug.
  • Men, sexually active with women of child-bearing age, who are not willing to practise effective contraception for the 48 week duration of the trial and for one-month after the last administration of the drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01237119

Layout table for location information
United Kingdom
NIHR BRU Centre for liver research, Queens Elizabeth University Hospital Birmingham
Birmingham, West Midlands, United Kingdom, B152TT
Sponsors and Collaborators
University of Birmingham
Wellcome Trust
Novo Nordisk A/S
Layout table for investigator information
Principal Investigator: Philip N Newsome, FRCPE PhD Centre for liver research, University of Birmingham
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: University of Birmingham Identifier: NCT01237119    
Other Study ID Numbers: HE2013
ISRCTN85774727 ( Registry Identifier: ISRCTN )
First Posted: November 9, 2010    Key Record Dates
Last Update Posted: March 23, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists